Season 3 - Ep.1: Strategic decisions in afib - Critical evaluation of clinical trials

Sep 26, 2024

Guest

Stephan Achenbach

Guest

Stephan Achenbach, a leading cardiology expert, joins Carlos Aguiar, a top atrial fibrillation researcher, Jane Armitage, a clinician renowned for her work on clinical trials, and Isabel Deisenhofer, an authority on cardiovascular study evaluation. They dive into strategic decisions in managing atrial fibrillation, discussing new guidelines that emphasize rhythm control and catheter ablation. The group also explores the importance of designing reliable clinical trials and the need for patient involvement in advanced cardiac treatment decisions.

Ask episode

Chapters

Transcript

Episode notes

Intro

00:00 • 6min

Guidelines for Atrial Fibrillation Management

05:55 • 5min

Involving Patients in Advanced Cardiac Treatment Decisions

11:07 • 2min

Designing Reliable Clinical Trials

13:19 • 6min

Critical Analysis of Clinical Trials and Case Studies in Echocardiography

18:58 • 3min

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology this Week: A concise summary of recent studies
Strategic decisions in atrial fibrillation
Critical evaluation of clinical trials
Snapshots

Host: Perry Elliott

Guests: Stephan Achenbach, Carlos Aguiar, Jane Armitage, Isabel Deisenhofer

Want to watch that episode? Go to: https://esc365.escardio.org/event/1720

Disclaimer

ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Jane Armitage and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo.

Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging, Inc., Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.